Effectiveness of a Web-Based Educational eHealth Platform on Women's Health Literacy About Phthalate Exposure: Randomized Controlled Trial.

J Med Internet ResSep 1, 2026 (epub)
Clinical ResearchObstetrics & GynecologyEndocrinologyOpen access

Ya Ling Shih, Shu Ching Wu, Pei Shan Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the effectiveness of the Phthalates Free eHealth platform in enhancing women's health literacy regarding phthalate exposure. Conducted with 114 women in Taipei, the study found a significant increase in total health literacy in the intervention group compared to the control group, with a mean increase of 9.93 points at 6 months (P < .001).

Key findings

  • The intervention group had a 9.93-point increase in total health literacy at 6 months compared to controls (P < .001).
  • Significant improvements were noted in health care (+1.52), disease prevention (+1.32), and health promotion (+1.12) domains (P = .001 for all).
  • High-engagement users scored significantly higher in overall health literacy (t 55 = -3.00; P = .004).
  • The System Usability Scale indicated high perceived usability with a mean score of 84.7.

Why it matters

Improving health literacy about phthalate exposure can empower women to make informed decisions regarding their health and reduce potential risks associated with endocrine disruptors. This study highlights the potential of eHealth platforms as effective educational tools.

Source

PubMed · PMID 42680485Free full text on PubMed Central

Published in J Med Internet Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.